Co-Authors
This is a "connection" page, showing publications co-authored by JEAN NICOLAS VAUTHEY and AHMED KASEB.
Connection Strength
3.487
-
Modified cisplatin/interferon a-2b/doxorubicin/5-fluorouracil (PIAF) chemotherapy in patients with no hepatitis or cirrhosis is associated with improved response rate, resectability, and survival of initially unresectable hepatocellular carcinoma. Cancer. 2013 Sep 15; 119(18):3334-42.
Score: 0.473
-
Development of a Novel Comprehensive Hepatocellular Carcinoma Outcome Prognostic Scoring System With Integration of Imaging Features. Oncologist. 2023 Dec 30.
Score: 0.245
-
Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial. Lancet Gastroenterol Hepatol. 2022 03; 7(3):208-218.
Score: 0.214
-
Impact of Integrating Insulin-Like Growth Factor 1 Levels into Model for End-Stage Liver Disease Score for Survival Prediction in Hepatocellular Carcinoma Patients. Oncology. 2020; 98(12):836-846.
Score: 0.196
-
Characteristics of atypical large well-differentiated hepatocellular carcinoma: a specific subtype of hepatocellular carcinoma? HPB (Oxford). 2020 04; 22(4):545-552.
Score: 0.182
-
Immunologic Correlates of Pathologic Complete Response to Preoperative Immunotherapy in Hepatocellular Carcinoma. Cancer Immunol Res. 2019 Sep; 7(9):1390-1395.
Score: 0.179
-
Natural History of T1N0M0 Hepatocellular Carcinoma: Large-Scale Study in the United States. Oncology. 2017; 93(4):233-242.
Score: 0.156
-
Local therapy reduces the risk of liver failure and improves survival in patients with intrahepatic cholangiocarcinoma: A comprehensive analysis of 362 consecutive patients. Cancer. 2017 04 15; 123(8):1354-1362.
Score: 0.150
-
Hepatocellular carcinoma recurrence after treatment with direct-acting antivirals: First, do no harm by withdrawing treatment. J Hepatol. 2016 10; 65(4):862-864.
Score: 0.145
-
Development and validation of insulin-like growth factor-1 score to assess hepatic reserve in hepatocellular carcinoma. J Natl Cancer Inst. 2014 May 09; 106(5).
Score: 0.125
-
Reassessing hepatocellular carcinoma staging in a changing patient population. Oncology. 2014; 86(2):63-71.
Score: 0.123
-
Prognostic indicators and treatment outcome in 94 cases of fibrolamellar hepatocellular carcinoma. Oncology. 2013; 85(4):197-203.
Score: 0.120
-
Surgical strategy for liver cancers in the era of effective chemotherapy. Liver Cancer. 2013 Jan; 2(1):47-54.
Score: 0.114
-
Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma. J Clin Oncol. 2011 Oct 10; 29(29):3892-9.
Score: 0.104
-
I-CLIP: improved stratification of advanced hepatocellular carcinoma patients by integrating plasma IGF-1 into CLIP score. Oncology. 2011; 80(5-6):373-81.
Score: 0.104
-
Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. Cancer. 2010 Apr 15; 116(8):1938-46.
Score: 0.095
-
Major hepatic resection for hepatocellular carcinoma with or without portal vein embolization: Perioperative outcome and survival. Surgery. 2009 Apr; 145(4):399-405.
Score: 0.088
-
Treatment Disparities Partially Mediate Socioeconomic- and Race/Ethnicity-Based Survival Disparities in Stage I-II Hepatocellular Carcinoma. Ann Surg Oncol. 2023 Nov; 30(12):7309-7318.
Score: 0.060
-
Salvage Locoregional Therapy Following Progression After Radiotherapy for Hepatocellular Carcinoma Is Associated with Improved Outcomes. J Gastrointest Surg. 2023 09; 27(9):1867-1875.
Score: 0.059
-
Evaluating the benefit of surgical resection for hepatocellular carcinoma with multifocality or intrahepatic vascular invasion. HPB (Oxford). 2023 Jul; 25(7):758-765.
Score: 0.058
-
Outcomes and Toxicities of Modern Combined Modality Therapy with Atezolizumab Plus Bevacizumab and Radiation Therapy for Hepatocellular Carcinoma. Cancers (Basel). 2022 Apr 09; 14(8).
Score: 0.054
-
Survival following liver transplantation for locally advanced, unresectable intrahepatic cholangiocarcinoma. Am J Transplant. 2022 03; 22(3):823-832.
Score: 0.053
-
Radiation-Associated Lymphopenia and Outcomes of Patients with Unresectable Hepatocellular Carcinoma Treated with Radiotherapy. J Hepatocell Carcinoma. 2021; 8:57-69.
Score: 0.050
-
Dose escalation of radiotherapy in unresectable extrahepatic cholangiocarcinoma. Cancer Med. 2018 10; 7(10):4880-4892.
Score: 0.042
-
Liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: a prospective case-series. Lancet Gastroenterol Hepatol. 2018 05; 3(5):337-348.
Score: 0.041
-
Comparative effectiveness of first-line radiofrequency ablation versus surgical resection and transplantation for patients with early hepatocellular carcinoma. Cancer. 2017 05 15; 123(10):1817-1827.
Score: 0.038
-
Prognosis of Fibrolamellar Carcinoma Compared to Non-cirrhotic Conventional Hepatocellular Carcinoma. J Gastrointest Surg. 2016 10; 20(10):1725-31.
Score: 0.037
-
Obesity Early in Adulthood Increases Risk but Does Not Affect Outcomes of Hepatocellular Carcinoma. Gastroenterology. 2015 Jul; 149(1):119-29.
Score: 0.033
-
Genetic variation in the PNPLA3 gene and hepatocellular carcinoma in USA: risk and prognosis prediction. Mol Carcinog. 2013 Nov; 52 Suppl 1:E139-47.
Score: 0.029
-
Gastric bleeding after radiation therapy for intrahepatic cholangiocarcinoma. Pract Radiat Oncol. 2013 Oct-Dec; 3(4):344-8.
Score: 0.028
-
Radiation treatment outcomes for unresectable hepatocellular carcinoma. Acta Oncol. 2011 Nov; 50(8):1191-8.
Score: 0.026
-
Association between hypothyroidism and hepatocellular carcinoma: a case-control study in the United States. Hepatology. 2009 May; 49(5):1563-70.
Score: 0.022
-
The association of family history of liver cancer with hepatocellular carcinoma: a case-control study in the United States. J Hepatol. 2009 Feb; 50(2):334-41.
Score: 0.021
-
Effect of different types of smoking and synergism with hepatitis C virus on risk of hepatocellular carcinoma in American men and women: case-control study. Int J Cancer. 2008 Oct 15; 123(8):1883-91.
Score: 0.021